logo
Share SHARE
FONT-SIZE Plus   Neg

KineMed And Pfizer Extend Collaboration On Type II Diabetes - Quick Facts

KineMed Inc. announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (PFE) for the advancement of novel approaches in metabolic disease, in particular Type II diabetes.

KineMed stated that the collaboration employs its novel dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.

"This platform has been useful in accelerating advancement and de-risking compounds in Type II diabetes. We look forward to continuing our work with Pfizer on their compounds in preclinical and clinical trials," said Marc Hellerstein, President, Chief Science Officer and Co-founder at KineMed.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
As most of us are painfully aware, the days of the pension are mostly gone. The percentage of employers still offering a traditional defined benefit pension plan to newly hired employees fell from about 50% to 5% between 1998 and 2015, according to advisory firm Willis Towers Watson. Many companies... Cruise Critic, a cruise reviews and information site, has announced its 10th annual Editors' Picks Awards for the best cruise ships and lines of 2017. The awards are given in three categories - ocean cruises, luxury cruises and river cruises. Viking Cruises, with five wins, topped the list of award winners. Following Viking in second spot was Crystal Cruises, with four awards. French real estate company Unibail-Rodamco SE Tuesday announced that it has entered into an agreement to acquire Australian shopping centre group Westfield Corp. in a deal that implies an enterprise value of $24.7 billion. The deal is expected to create the world's premier developer and operator of flagship shopping destinations with 61.1 billion euros or $72.2 billion of Gross Market Value.
comments powered by Disqus
Follow RTT